Antibody cocktail from Greek-American company “brakes” Covid-19

THE Greek-American Regeneron Pharmaceuticals announced that the “cocktail” of antibodies against Covid-19 that he was developing protected two species of guinea pigs (36 macaques and 50 hamster rodents) from getting sick, while at the same time curing those who had the infection.The company said the combination of the two monoclonal antibodies almost stopped the virus from infecting and minimizing infection in animals that had already been infected. However, the prophylactic effect was much lower with the lower dose of the drug.

According to Reuters, Regeneron places the results of its drug at higher levels than those of the Covid-19 vaccine in experimental animals. She believes that her drug can provide clinical benefits for both the prevention and treatment of the disease.

The above, of course, can only be confirmed after testing the cocktail in humans, because positive results in animals do not equate to similar success in human patients. Regeneron has already begun third-degree clinical trials in humans and has signed a $ 450 million supply contract with the US government if the drug proves effective.

The monoclonal antibodies that Regeneron is working on may be the future of the fight against the disease, and they are already being used against cancer and other diseases. Regeneron is at the forefront of creating such antibodies.

The company’s executives played an important role in this avant-garde. Specifically, the co-founder, executive chairman and chief scientist of the company, Greek-American George Gianakopoulos (PhD from Columbia University, New York), the Chairman of the Board, the Greek-American Roy Vaggelos (Pindaros Vagielos) and the head of the antibody research, of Greek origin Vice President Christos Kyratsous.

Source: ΑΠΕ-ΜΠΕ

https://www.corona24news.com/